title: Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.
abstract: Genetic transfer of neutralizing antibodies (Abs) has been shown to confer strong and persistent protection against bacterial and viral infectious agents. Although it is well established that for many exogenous neutralizing Abs increased antigen affinity correlates with protection, the effect of antigen affinity on Abs produced in situ after adenoviral gene transfer has not been examined. The mouse IgG2b monoclonal Ab, 2C12.4, recognizes the Yersinia pestis type III secretion apparatus protein, LcrV (V antigen), and confers protection in mice when administered as an IgG intraperitoneally or after genetic immunization with engineered, replication-defective serotype 5 human adenovirus (Ad). The 2C12.4 Ab was expressed as a single-chain variable fragment (scFv) in Escherichia coli and was shown to display an equilibrium dissociation constant (K(D))=3.5 nM by surface plasmon resonance analysis. The 2C12.4 scFv was subjected to random mutagenesis, and variants with increased affinity were isolated by flow cytometry using the anchored periplasmic expression bacterial display system. After a single round of mutagenesis, variants displaying up to 35-fold lower K(D) values (H8, K(D)=100 pM) were isolated. The variable domains of the H8 scFv were used to replace those of the parental 2C12.4 IgG encoded in the Ad vector, AdalphaV, giving rise to AdalphaV.H8. The two adenoviral vectors resulted in similar titers of anti-V antigen Abs 3 days after immunization, with 10(9), 10(10) or 10(11) particle units (pu). After intranasal challenge with 363 LD(50) (lethal dose, 50%) of Y. pestis CO92, 54% of the mice immunized with 10(10) pu of AdalphaV.H8 survived through the 14 day end point compared with only 15% survivors for the group immunized with AdalphaV expressing the lower-affinity 2C12.4 (P<0.04; AdalphaV versus AdalphaV.H8). These results indicate that affinity maturation of a neutralizing Ab delivered by genetic transfer may confer increased protection not only for Y. pestis challenge but also possibly for other pathogens.
authors.affiliation: Department of Chemical Engineering, The University of Texas at Austin, TX 78712, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Van Blarcom
authors.forename: C
authors.initials: C
authors.lastname: Sofer-Podesta
authors.forename: J
authors.initials: J
authors.lastname: Ang
authors.forename: J L
authors.initials: JL
authors.lastname: Boyer
authors.forename: R G
authors.initials: RG
authors.lastname: Crystal
authors.forename: G
authors.initials: G
authors.lastname: Georgiou
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics; D057134:Antibodies, Neutralizing / Q000627:therapeutic use*; D000915:Antibody Affinity / Q000235:genetics*; D000942:Antigens, Bacterial / Q000276:immunology*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010930:Plague / Q000401:mortality; D052899:Pore Forming Cytotoxic Proteins / Q000276:immunology*; D015010:Yersinia pestis / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000942:Antigens, Bacterial; C043908:LcrV protein, Yersinia; D052899:Pore Forming Cytotoxic Proteins
references.citation: Ann Med. 2009;41(5):322-31
references.pmid: 19234897
references.citation: Ann N Y Acad Sci. 2006 Oct;1078:223-35
references.pmid: 17114713
references.citation: Infect Immun. 2006 May;74(5):3068-70
references.pmid: 16622253
references.citation: Proteins. 1996 May;25(1):130-3
references.pmid: 8727325
references.citation: Nat Biotechnol. 2001 Jun;19(6):537-42
references.pmid: 11385457
references.citation: J Mol Biol. 2007 May 4;368(3):652-65
references.pmid: 17362988
references.citation: Nat Biotechnol. 2002 Jun;20(6):597-601
references.pmid: 12042864
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6179-85
references.pmid: 17062695
references.citation: J Mol Biol. 2005 Jul 1;350(1):126-44
references.pmid: 15907931
references.citation: J Virol. 1996 Nov;70(11):7498-509
references.pmid: 8892868
references.citation: Cell. 1992 Jan 10;68(1):143-55
references.pmid: 1370653
references.citation: J Clin Pharmacol. 2006 Jan;46(1):10-20
references.pmid: 16397279
references.citation: FEBS J. 2005 May;272(10):2591-601
references.pmid: 15885107
references.citation: Immunol Rev. 2008 Oct;225:256-71
references.pmid: 18837787
references.citation: Anal Biochem. 1995 Jan 1;224(1):347-53
references.pmid: 7710092
references.citation: J Mol Recognit. 1999 Sep-Oct;12(5):279-84
references.pmid: 10556875
references.citation: Hum Gene Ther. 2005 Feb;16(2):157-68
references.pmid: 15761256
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9193-8
references.pmid: 15197275
references.citation: Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):686-706
references.pmid: 16839640
references.citation: Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1254-6
references.pmid: 7877964
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10
references.pmid: 16537476
references.citation: Oncologist. 2008 Jun;13(6):725-32
references.pmid: 18586928
references.citation: Infect Immun. 2005 Dec;73(12):8362-8
references.pmid: 16299334
references.citation: Protein Expr Purif. 2000 Feb;18(1):1-10
references.pmid: 10648163
references.citation: Nat Biotechnol. 2005 May;23(5):584-90
references.pmid: 15834403
references.citation: J Infect Dis. 2006 Nov 1;194(9):1249-57
references.pmid: 17041851
references.citation: J Immunol Methods. 2003 May 1;276(1-2):185-96
references.pmid: 12738372
references.citation: Infect Immun. 2009 Apr;77(4):1561-8
references.pmid: 19124600
references.citation: Nat Protoc. 2008;3(11):1766-77
references.pmid: 18948976
references.citation: Infect Immun. 2003 Apr;71(4):2234-8
references.pmid: 12654847
references.citation: Mov Disord. 2004 Mar;19 Suppl 8:S101-8
references.pmid: 15027061
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8466-71
references.pmid: 15939870
references.citation: Infect Immun. 2005 Feb;73(2):795-802
references.pmid: 15664918
references.citation: Cancer Gene Ther. 2001 Oct;8(10):815-26
references.pmid: 11687905
references.citation: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3809-13
references.pmid: 8170992
references.citation: J Mol Biol. 2007 Jun 8;369(3):631-9
references.pmid: 17462668
references.citation: Microbes Infect. 2006 Jan;8(1):273-84
references.pmid: 16182593
references.citation: Infect Immun. 1997 Nov;65(11):4476-82
references.pmid: 9353022
references.citation: Mol Ther. 2008 Jan;16(1):203-9
references.pmid: 18059375
references.citation: Infect Immun. 2005 Oct;73(10):6885-91
references.pmid: 16177368